You may not recall the one-off 500,000th example of the G-Class that Mercedes dressed up to look like an original 280 GE when ...

With a forward P/E ratio of 5.79 and a PEG ratio of 0.05, BioNTech played a huge part in formulating the BioNTech-Pfizer vaccine ... supplies ferro-alloys; along with processes ferrous and ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the ...

Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug. (Image Credits: Reuters) Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...

On April 14, Pfizer announced it would discontinue development of an experimental weight-management pill. Pfizer is facing patent expirations for several of its biggest revenue streams.

Pfizer (NYSE:PFE) said on Wednesday. This decision includes Abrysvo, approved for the prevention of RSV-related respiratory diseases in adults aged 18 to 59 at increased risk of severe disease.

Novavax recipients had 1.7 symptoms on average vs. 2.8 for Pfizer-BioNTech in SHIELD-Utah. 24.2% of Novavax recipients had Grade 2+ symptoms vs. 43.8% of Pfizer-BioNTech recipients. Markets are ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...